PG
ACAD icon

PEAK6 Group’s Acadia Pharmaceuticals ACAD Stock Holding History

PEAK6 Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-51,500
Closed -$2.16M – 5060
2015
Q2 		$2.16M Buy
+51,500
New +$1.99M 0.01% 1414

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Group's ACAD Position: Q2 2015 in Review

PEAK6 Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2015, closing a stake of 4,800 shares — an estimated $186K sold.

PEAK6 Group first reported a position in ACAD in Q1 2015 and held it in 1 quarter. The position peaked at $156K in Q1 2015. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

  • PEAK6 Group reported no remaining Acadia Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • PEAK6 Group sold 4,800 Acadia Pharmaceuticals shares in Q2 2015, an estimated $186K.
  • PEAK6 Group first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • PEAK6 Group's Acadia Pharmaceuticals position peaked at $156K in Q1 2015.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on PEAK6 Group's 13F filing for Q2 2015, filed 11 Aug 2015.